Natural Product (NP) Details
| General Information of the NP (ID: NP9550) | |||||
|---|---|---|---|---|---|
| Name |
Garcinol
|
||||
| Synonyms |
Camboginol; 78824-30-3; AC1Q1NUM; GTPL7001; QDKLRKZQSOQWJQ-SMDXAGPFSA-N; ZINC4098424; AKOS025142024; (1S,5R,7R)-3-[(3,4-dihydroxyphenyl)(hydroxy)methylidene]-6,6-dimethyl-1-[(2S)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-5,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]nonane-2,4,9-trione; (1R,5R,7R)-3-(3,4-Dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2S)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-Bicyclo[3.3.1]non-3-ene-2,9-dione
Click to Show/Hide
|
||||
| Species Origin | Cicer arietinum ... | Click to Show/Hide | |||
| Cicer arietinum | |||||
| Garcinia dulcis | |||||
| Garcinia indica | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.869
MDCK Permeability
-4.674
PAMPA
- -
HIA
- - -
Distribution
VDss
0.054
PPB
90.6%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
-
CYP2C19 substrate
- -
CYP2C9 inhibitor
+++
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
3.675
T1/2
1.606
Toxicity
DILI
- -
Rat Oral Acute Toxicity
++
FDAMDD
++
Respiratory
+
Human Hepatotoxicity
++
Ototoxicity
++
Drug-induced Nephrotoxicity
+
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C38H50O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=CCC1CC2(C(=O)C(=C(C3=CC(=C(C=C3)O)O)O)C(=O)C(C2=O)(C1(C)C)CC=C(C)C)CC(CC=C(C)C)C(=C)C)C
|
||||
| InChI |
1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-41H,7,13,15,18,20-21H2,1-6,8-10H3/b32-31-/t27-,28+,37+,38-/m0/s1
|
||||
| InChIKey |
DTTONLKLWRTCAB-BZSUNBQASA-N
|
||||
| CAS Number |
CAS 78824-30-3
|
||||
| Herb ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Garcinol in combination with DDP promoted cell apoptosis in human ovarian cancer cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Histone acetyltransferase KAT2B (KAT2B) | Molecule Info | [3] | |
| Histone acetyltransferase KAT6B (KAT6B) | Molecule Info | [3] | ||
| KEGG Pathway | cAMP signaling pathway | Click to Show/Hide | ||
| 2 | HIF-1 signaling pathway | |||
| 3 | FoxO signaling pathway | |||
| 4 | Cell cycle | |||
| 5 | Wnt signaling pathway | |||
| 6 | Notch signaling pathway | |||
| 7 | TGF-beta signaling pathway | |||
| 8 | Adherens junction | |||
| 9 | Jak-STAT signaling pathway | |||
| 10 | Long-term potentiation | |||
| 11 | Melanogenesis | |||
| 12 | Thyroid hormone signaling pathway | |||
| 13 | Glucagon signaling pathway | |||
| 14 | Huntington's disease | |||
| 15 | Tuberculosis | |||
| 16 | Hepatitis B | |||
| 17 | Influenza A | |||
| 18 | HTLV-I infection | |||
| 19 | Herpes simplex infection | |||
| 20 | Epstein-Barr virus infection | |||
| 21 | Pathways in cancer | |||
| 22 | Viral carcinogenesis | |||
| 23 | MicroRNAs in cancer | |||
| 24 | Renal cell carcinoma | |||
| 25 | Prostate cancer | |||
| Panther Pathway | p53 pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Signaling events mediated by HDAC Class III | |||
| 3 | E2F transcription factor network | |||
| 4 | Signaling events mediated by HDAC Class I | |||
| 5 | FoxO family signaling | |||
| 6 | Regulation of Androgen receptor activity | |||
| 7 | Retinoic acid receptors-mediated signaling | |||
| 8 | p53 pathway | |||
| Reactome | Pre-NOTCH Transcription and Translation | Click to Show/Hide | ||
| 2 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 3 | NOTCH1 Intracellular Domain Regulates Transcription | |||
| 4 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||
| 5 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||
| 6 | HATs acetylate histones | |||
| 7 | Notch-HLH transcription pathway | |||
| 8 | RNA Polymerase I Transcription Initiation | |||
| 9 | Regulation of gene expression by Hypoxia-inducible Factor | |||
| 10 | RORA activates gene expression | |||
| 11 | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| 12 | Polo-like kinase mediated events | |||
| 13 | PPARA activates gene expression | |||
| 14 | Formation of the beta-catenin:TCF transactivating complex | |||
| 15 | NOTCH2 intracellular domain regulates transcription | |||
| 16 | DNA Damage/Telomere Stress Induced Senescence | |||
| 17 | LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | |||
| 18 | Attenuation phase | |||
| 19 | Transcriptional regulation of white adipocyte differentiation | |||
| 20 | Circadian Clock | |||
| 21 | HDR through Single Strand Annealing (SSA) | |||
| 22 | HDR through Homologous Recombination (HRR) | |||
| 23 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| 24 | Nonhomologous End-Joining (NHEJ) | |||
| 25 | Processing of DNA double-strand break ends | |||
| 26 | Presynaptic phase of homologous DNA pairing and strand exchange | |||
| 27 | Formation of TC-NER Pre-Incision Complex | |||
| 28 | Dual incision in TC-NER | |||
| 29 | Gap-filling DNA repair synthesis and ligation in TC-NER | |||
| 30 | G2/M DNA damage checkpoint | |||
| 31 | TRAF3-dependent IRF activation pathway | |||
| 32 | TRAF6 mediated IRF7 activation | |||
| 33 | Factors involved in megakaryocyte development and platelet production | |||
| WikiPathways | Nuclear Receptors Meta-Pathway | Click to Show/Hide | ||
| 2 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 3 | Notch Signaling Pathway | |||
| 4 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
| 5 | Androgen receptor signaling pathway | |||
| 6 | SIDS Susceptibility Pathways | |||
| 7 | Notch Signaling Pathway | |||
| 8 | TGF Beta Signaling Pathway | |||
| 9 | Wnt Signaling Pathway and Pluripotency | |||
| 10 | IL-4 Signaling Pathway | |||
| 11 | TGF beta Signaling Pathway | |||
| 12 | Kit receptor signaling pathway | |||
| 13 | Aryl Hydrocarbon Receptor Pathway | |||
| 14 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 15 | Cytosolic sensors of pathogen-associated DNA | |||
| 16 | Pre-NOTCH Expression and Processing | |||
| 17 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 18 | Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||
| 19 | Signaling by NOTCH1 | |||
| 20 | Signaling by NOTCH2 | |||
| 21 | Aryl Hydrocarbon Receptor | |||
| 22 | Integrated Pancreatic Cancer Pathway | |||
| 23 | Signaling Pathways in Glioblastoma | |||
| 24 | Integrated Breast Cancer Pathway | |||
| 25 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 26 | Factors involved in megakaryocyte development and platelet production | |||
| 27 | Circadian Clock | |||
| 28 | Cell Cycle | |||
